Skip to contentT
Thermo Fisher Scientific Inc.
T
TMOThermo Fisher Scientific Inc. Q2 2024 · 10-Q
Revenue$10.54B$10.54B−1.4% vs Q2 2023 Net Income$1.55B$1.55B+13.7% vs Q2 2023 EPS Diluted$4.04$4.04+15.1% vs Q2 2023 Operating Income$1,820,000,000+15.3% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Thermo Fisher Scientific Inc. · CIK 97745 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,659,000,000+32.1% Margins · derivedOperating margin17.3%+2.5 pt vs Q2 2023
Net margin14.7%+1.9 pt vs Q2 2023
ended Jun 29, 2024 · filed Aug 2, 2024 · 34 d after period end